This is a Phase II study that will be open label and include a total of 17 patients who will receive the investigational product. PG will be defined by the investigator on the basis of results from clinical, histological and laboratory assessments. These patients will undergo 28 weeks of guselkumab dosed every 4 weeks and a stable dose of prednisone dosed daily with follow-up until week 40.
© 2026 Paid Trials | All Right Reserved.
Step 1: Add a recruitment campaign (optional)
Our expert team has 10+ years running successful recruitment campaigns for clinical research sites
Your plan includes posting your clinical trials on our recruitment portal and mobile apps. Boost your trials with targeted advertising campaigns to reach more participants, faster.
We handle everything: audience targeting, creative development, geo targeting to your site locations, and ongoing optimizations. Qualified participant inquiries flow directly into your dashboard. Inquiries typically begin within a few days and continue throughout the campaign.
